Danilov Alexey V, Kambhampati Thiruvengadam Swetha, Linton Kim, Cumings Karen, Chirikov Viktor, Mutebi Alex, Bains Chawla Savreet, Chhibber Anindit, Rivas Navarro Fernando, Marques Gonçalves Felipe, Wang Anthony, Ding Zhijie, Alshreef Abualbishr, Favaro Elena, Hoehn Daniela, Sureda Anna
Department of Hematology, City of Hope National Medical Center, Duarte, CA.
The Christie NHS Foundation Trust, Manchester Cancer Research Center, and Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
Blood Adv. 2025 Aug 12;9(15):3754-3765. doi: 10.1182/bloodadvances.2024015274.
This matching-adjusted indirect comparison evaluated the efficacy of epcoritamab vs standard of care (SOC), mosunetuzumab, or odronextamab, and assessed safety vs mosunetuzumab and odronextamab. Individual patient-level data from the EPCORE NHL-1 follicular lymphoma (FL) cohort for epcoritamab were used with pooled data from SCHOLAR-5 for SOC (mostly chemoimmunotherapy [CIT]), and aggregate data from GO29781 for mosunetuzumab and ELM-2 for odronextamab. Trial populations were match-adjusted using propensity score weights for key baseline characteristics. Compared with SOC/CIT, epcoritamab provided significantly higher response rates (overall response rate [ORR], 90.9% vs 56.8%; P < .001; complete response [CR] rate, 73.7% vs 32.0%; P < .001). Epcoritamab showed numerically higher ORR (90.9% vs 80.0%; P = .067) and CR rate (72.8% vs 60.0%; P = .159) vs mosunetuzumab. Epcoritamab provided significantly higher ORR (91.5% vs 80.5%; P = .026) and numerically lower CR rate (67.5% vs 73.4%; P = .428) vs odronextamab. Epcoritamab did not have any grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS; any grade) events compared with CRS (grade ≥3) in 2.2% and 3.9% and ICANS in 4.4% and 0.8% of patients treated with mosunetuzumab and odronextamab, respectively (P < .001). In addition to being a convenient subcutaneous option, epcoritamab showed significantly superior response rates and survival outcomes vs SOC/CIT among patients with relapsed or refractory FL after ≥2 systemic therapies. Epcoritamab also exhibited clinically relevant, numerically higher ORRs and demonstrated improved safety for CRS (grade ≥3) and ICANS vs mosunetuzumab or odronextamab. These trials were registered at www.ClinicalTrials.gov as #NCT03625037, #NCT02500407, and #NCT03888105.
这项匹配调整间接比较评估了epcoritamab与标准治疗（SOC）、mosunetuzumab或odronextamab的疗效，并评估了与mosunetuzumab和odronextamab相比的安全性。使用来自EPCORE NHL-1滤泡性淋巴瘤（FL）队列中epcoritamab的个体患者水平数据，以及来自SCHOLAR-5中SOC（主要是化疗免疫疗法[CIT]）的汇总数据，还有来自GO29781中mosunetuzumab的汇总数据和来自ELM-2中odronextamab的汇总数据。使用倾向评分权重对关键基线特征进行试验人群匹配调整。与SOC/CIT相比，epcoritamab的缓解率显著更高（总缓解率[ORR]，90.9%对56.8%；P <.001；完全缓解[CR]率，73.7%对32.0%；P <.001）。与mosunetuzumab相比，epcoritamab的ORR在数值上更高（90.9%对80.0%；P = 0.067），CR率也更高（72.8%对60.0%；P = 0.159）。与odronextamab相比，epcoritamab的ORR显著更高（91.5%对80.5%；P = 0.026），CR率在数值上更低（67.5%对73.4%；P = 0.428）。与分别接受mosunetuzumab和odronextamab治疗的患者中2.2%出现3级及以上细胞因子释放综合征（CRS）和3.9%出现CRS、4.4%出现免疫效应细胞相关神经毒性综合征（ICANS）以及0.8%出现ICANS相比，epcoritamab未出现任何3级及以上CRS或ICANS（任何级别）事件（P <.001）。除了是一种方便的皮下给药选择外，在接受≥2种全身治疗后的复发或难治性FL患者中，epcoritamab与SOC/CIT相比显示出显著更高的缓解率和生存结果。与mosunetuzumab或odronextamab相比，epcoritamab还表现出临床上相关的、数值上更高的ORR，并且在CRS（3级及以上）和ICANS方面显示出更好的安全性。这些试验已在www.ClinicalTrials.gov上注册，注册号为#NCT03625037、#NCT02500407和#NCT03888105。
